

NHSN Antimicrobial Resistance (AR) Option: Incidence and Prevalence Reports

Virgie S. Fields, MS, CPH, CIC Public Health Analyst Lantana Consulting Group | Contractor for the Division of Healthcare Quality Promotion, CDC

NHSN Annual Training March 2023

1

Objectives

- Discuss what is included in the six new NHSN AR Option incidence and prevalence reports
- Modify, run, and interpret the Rate Table Hospital-onset Antimicrobial Resistance Incidence report
- Modify, run, and interpret the Rate Table Community-onset Positive Culture Prevalence by Organism report
- Discuss what happens when denominator data are not reported for a time period

What's included in the AR Option Incidence and Prevalence Reports?

Numerator: AR Events

AR Events

- Event data: Isolate-level susceptibility results for specific organisms
- Qualifying isolate criteria for an AR Event:
 - 1. Collected in an eligible location/unit
 - 2. Collected from one of four specimen types:
 - Blood
 - Cerebral spinal fluid (CSF)
 - Urine
 - Lower respiratory
 - 3. Eligible organism identified (refer to next slide)
 - 4. Antimicrobial susceptibility testing must be completed
 - Qualifies for submission regardless of susceptibility results



Eligible Organisms

- All Acinetobacter species
- Candida albicans; auris; glabrata; parapsilosis; tropicalis
- Citrobacter amalonaticus; freundii; koseri
- All *Enterobacter* species
- All *Enterococcus* species
- Escherichia coli

6

 Klebsiella aerogenes; oxytoca; pneumoniae

- Morganella morganii
- Proteus mirabilis; penneri; vulgaris
- Pseudomonas aeruginosa
- Serratia marcescens
- Staphylococcus aureus
- Stenotrophomonas maltophilia
- Streptococcus agalactiae (Group B Streptococcus)
- Streptococcus pneumoniae

AUR Module Protocol: <u>https://www.cdc.gov/nhsn/pdfs/pscmanual/11pscaurcurrent.pdf</u> AR CDA Toolkit: <u>https://www.cdc.gov/nhsn/cdaportal/toolkits.html</u>

Organism/Agent Combinations

- Selected antimicrobial agents are required to be reported for each of the organisms per specimen type
 - Full list (i.e., drug panels) can be found in the NHSN AUR Module Protocol: <u>http://www.cdc.gov/nhsn/PDFs/pscManual/11pscAURcurrent.pdf</u>

Organism	Specimen Type	Antimicrobial Agents
Acinetobacter	Blood, Urine, Lower	Amikacin
(All Acinetobacter species	Respiratory, CSF	Ampicillin-sulbactam
noted in the AR Option		Cefepime
Pathogen Roll-up		Cefiderocol
Workbook)		Cefotaxime
		Ceftazidime
		Ceftriaxone
		Ciprofloxacin
		Colistin
		Doripenem
		Doxycycline
		Gentamicin
		Imipenem with Cilastatin
		Levofloxacin
		Meropenem
		Minocycline
		Piperacillin-tazobactam
		Polymyxin B
		Tobramycin
		Trimethoprim-sulfamethoxazole
	Additional Agents for Urine	Tetracycline

Hospital-onset vs. Community-onset

- NHSN classifies AR events as hospital-onset or community-onset based on the specimen collection date and date of admission
- Hospital-onset: Specimen collected in an inpatient location on or after day 4 (where day 1 is date of admission)
- Community-onset: Specimen collected in an inpatient or outpatient location ≤ 3 days after admission to the facility (i.e., days 1, 2, or 3)



Denominator: AR Summary Data

Patient Days, Admissions, Encounters

AR Summary Data

- Facilities can submit two types of AR summary records:
 - 1. Facility-wide inpatient (aka FacWideIN)
 - Report patient days and admissions for <u>ALL</u> inpatient locations combined
 - 2. Outpatient locations
 - Report outpatient encounters for <u>EACH</u> reportable individual outpatient location (i.e., ED, pediatric ED, 24-hour observation area)
- Summary records are <u>not</u> submitted for:
 - Individual inpatient locations
 - Combined outpatient locations (FacWideOUT) or outpatient locations beyond those mapped as the three location types above

Patient Days

- Total number of patient days for all facility inpatient locations (FacWideIN) collected at the same time each day combined for the month ("daily census")
 - Reported for FacWideIN only
 - Same definition used for HAI reporting

Admissions

- Total number of admissions for all facility inpatient locations (FacWideIN) combined for the month
 - A patient is counted as an admission when they arrive in an NHSN designated inpatient location regardless of patient status (for example, inpatient, observation)
 - Reported for FacWideIN only
 - Same definition used for AU Option

Encounters

- Total number of patient visits to the given outpatient location (specifically: ED, pediatric ED, 24-hour observation area)
 - A visit to an eligible outpatient location counts as a single encounter
- Example scenarios:
 - If a patient arrives in the ED on Monday, then is transferred to the 24hour Observation Area on Tuesday, the patient should be counted only as 1 encounter within the ED and zero encounters within the 24-hour Observation Area.
 - If a patient arrives in the ED at 07:00 on Monday, is discharged at 11:00 on Monday then returns to the ED at 18:00 on Monday, that patient counts as two separate encounters for the ED.

Calculating Incidence and Prevalence Rates

Incidence and Prevalence Rates

Incidence Rate:

Hospital-onset AR Events
Patient Days
×10,000

Community-onset Prevalence Rate:

Community–onset AR Events from inpatient **and** outpatient locations ×10,000

Admissions

Outpatient Prevalence Rate:

Community–onset AR Events from outpatient locations **only** ×10.000

Encounters

Rates are provided for each individual specimen type (i.e., blood, urine, CSF, lower respiratory) and for all specimen types combined

AR Pathogen Groups

- Individual rate tables for 10 pathogen groups
 - Acinetobacter
 - Candida
 - Enterobacterales_all (E. coli, Enterobacter, Klebsiella)
 - Enterobacterales_expanded (E. coli, Enterobacter, Klebsiella, Citrobacter, Morganella morganii, Proteus, Serratia marcescens)
 - Enterococcus
 - Pseudomonas aeruginosa
 - Staphylococcus aureus
 - Stenotrophomonas maltophilia
 - *Streptococcus agalactiae* (Group B *Streptococcus*)
 - Streptococcus pneumoniae

AR Phenotypes

- Individual rate tables for 16 AR phenotypes
 - Methicillin-resistant *Staphylococcus aureus*
 - Carbapenem-resistant (CR) Enterobacterales (expanded)
 - CR Enterobacterales (*E. coli, Klebsiella*, or *Enterobacter*)
 - CR E. coli
 - CR Enterobacter spp. and Klebsiella aerogenes
 - CR Klebsiella pneumoniae/oxytoca
 - Carbapenem-non-susceptible *Pseudomonas* aeruginosa
 - Extended-spectrum cephalosporin-resistant *E. coli*
 - Extended-spectrum cephalosporin-resistant Klebsiella pneumoniae/oxytoca

- Multidrug-resistant (MDR) Pseudomonas aeruginosa
- Carbapenem-non-susceptible Acinetobacter spp.
- MDR Acinetobacter spp.
- Vancomycin-resistant *Enterococcus faecalis*
- Vancomycin-resistant Enterococcus faecium
- Fluconazole-resistant Candida albicans/auris/glabrata/parapsilosis/tropicalis
- Drug-resistant *Streptococcus pneumoniae*

AR Phenotype Definitions: https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/aur/ar-phenotype-definitions-508.pdf

Where can I find the new AR Option Incidence and Prevalence Reports?

First, Generate Data Sets

- Click Analysis then Generate
 Data Sets
- Newly uploaded data do not appear until you generate new data sets



AR Option Incidence and Prevalence Reports

- Click Analysis then Reports
- On the Analysis Reports page:

 \rightarrow Antimicrobial Use and Resistance Module

- \rightarrow Antimicrobial Resistance Data
- Six new rate tables available
 - Two incidence reports
 - By phenotype (#1) & by pathogen group (#4)
 - Four prevalence reports
 - By phenotype (#2, #3) & by pathogen group (#5, #6)

Analysis Reports	
Expand All Collapse All Search	
🔤 Device-Associated (DA) Module	
🔤 Procedure-Associated (PA) Module	
🔤 HAI Antimicrobial Resistance (DA+PA Modules)	
🗕 🔚 Antimicrobial Use and Resistance Module	
🖙 📴 Antimicrobial Use Data	
🔚 Targeted Assessment for Stewardship (TAS) Reports	
🔚 Antimicrobial Use Data - 2014 Baseline SAARs	
🗕 🔚 Antimicrobial Resistance Data	
🔤 Line Listing - All Antimicrobial Resistance Events	
🔤 💵 Bar Chart - All Antimicrobial Resistance Events	
Line Listing - Antimicrobial Resistant Organisms	
Frequency Table - Antimicrobial Resistant Organisms	
Facility-wide antibiogram (Percent Susceptible) and Percent Tested	
Rate Table - Antimicrobial Resistance Percentages	
Rate Table - Hospital-onset Antimicrobial Resistance Incidence	
🔹 🖓 Rate Table - Community-onset Antimicrobial Resistance Prevalence	
🔹 🔤 Rate Table - Outpatient Antimicrobial Resistance Prevalence	
Rate Table - Hospital-onset Positive Culture Incidence by Organism	
💶 🔤 🔤 🚰 Rate Table - Community-onset Positive Culture Prevalence by Organ	nism
6 Rate Table - Outpatient Positive Culture Prevalence by Organism	
🛄 🔚 Line Listing - All AR Summary Data	

Example: Rate Table – Hospital-onset Antimicrobial Resistance Incidence Report (New Rate Table #1)

Note: The following example uses fictitious data for illustrative purposes only.

Modifying the Rate Table



Rate Table – Time Period Tab

dify "Rate Table	- Hospit	al-onset /	Antimicrob	ial Resistance Incider	ice"		
Show descriptive	variable r	names <u>(Prin</u>	<u>nt List)</u>		Analysis Data Set: AntibiogramRates_HO_PHEN	Type: Rate Table	Last Generated: <u>March 8, 2023 9:22 AM</u>
Title/Format	Time F	Period	Filters	Display Options			
Time Deried:							
Date Variable		Beginning		Ending			
Summary~Yr	~	2021		2022	🗶 Clear Time Period		
🗆 Enter Date	variable	/Time per	iod at the t	ime you click the Run	button		
						► Run 🗖	Save iii Export Close

Rate Table – Filters Tab

Modify "Rate Table - Hospital-onset Antimicrobial Resistance Incidence"			
Show descriptive variable names (Print List)	Analysis Data Set: AntibiogramRates_HO_PHEN	Type: Rate Table	Last Generated: <u>March 8, 2023 9:22 AM</u>
Title/Format Time Period Filters Display Options			
Additional Filters: 😨 Show 🛛 🗶 Clear			
AND OR			Add group
AND OR			Add rule
Resistant Organism 🗸 equal 🗸 Carbapenem-r	non-susceptible Acinetobacter spp.		✓ Delete
		🕨 Run 🛛 🖶 S	ave 🛍 Export Close

Rate Table – Display Options Tab

- Rates available by Quarter, Half-Year, Year, and Cumulative
 - Default is by Quarter
- Users do not have the option to generate rates by Month

Modify "Rate Table - Hospital-onset Antimicrobial Resistance Incidence"			
Show descriptive variable names (Print List)	Analysis Data Set: AntibiogramRates_HO_PHEN	Type: Rate Table Last Generated: March 8, 2023 9:22 AM	
Title/Format Time Period Filters Display Options			
Rate Table Options: Group by: Summary~Yr			
		► Run 🖩 Save 🏟 Export Close	

Rate Table – Output

National Healthcare Safety Network Rate Table for Incidence of Hospital-onset Antimicrobial Resistance by Phenotype (per 10,000 patient days) As of: March 8, 2023 at 5:59 PM Date Range: ANTIBIOGRAMRATES_HO_PHEN summaryYr 2021 to 2022 If (((phenotype_AR = "carbNS_Acine_AR")))

Facility Org ID=10009 Phenotype Description=Carbapenem-non-susceptible Acinetobacter spp.

Phenotype_AR	Summary Yr	Patient Days	Blood Count	Blood Incidence Rate	CSF Count	CSF Incidence Rate	LRS Count	LRS Incidence Rate	Urine Count	Urine Incidence Rate	All Specimen Type Count	All Specimen Type Incidence Rate
carbNS_Acine_AR	2021	4785	0	0	0	0	1	2.09	3	6.27	4	8.36
carbNS_Acine_AR	2022	5150	5	9.71	4	7.77	18	34.95	4	7.77	31	60.19

1. This phenotype includes any Acinetobacter spp. that has tested either Intermediate (I) or Resistant (R) to imipenem, meropenem, or doripenem.

2. Incidence: number of hospital-onset AR Events / patient days * 10,000.

Rate Table Interpretation – Phenotype_AR

- Rate table for incidence of hospital-onset carbapenem-non-susceptible Acinetobacter spp. per 10,000 patient days
 - Includes any Acinetobacter spp. that has tested either Intermediate (I) or Resistant (R) to imipenem, meropenem, or doripenem

National Healthcare Safety Network

Rate Table for Incidence of Hospital-onset Antimicrobial Resistance by Phenotype (per 10,000 patient days)

As of: March 8, 2023 at 5:59 PM

Date Range: ANTIBIOGRAMRATES_HO_PHEN summaryYr 2021 to 2022

if (((phenotype_AR = "carbNS_Acine_AR")))

Facility Org ID=10009 Phenotype Description=Carbapenem-non-susceptible Acinetobacter spp.

Phenotype_AR	Summary Yr	Patient Days	Blood Count	Blood Incidence Rate	CSF Count	CSF Incidence Rate	LRS Count	LRS Incidence Rate	Urine Count	Urine Incidence Rate	All Specimen Type Count	All Specimen Type Incidence Rate
carbNS_Acine_AR	2021	4785	0	0	0	0	1	2.09	3	6.27	4	8.36
carbNS_Acine_AR	2022	5150	5	9.71	4	7.77	18	34.95	4	7.77	31	60.19

1. This phenotype includes any Acinetobacter spp. that has tested either Intermediate (I) or Resistant (R) to imipenem, meropenem, or doripenem.

2. Incidence: number of hospital-onset AR Events / patient days * 10,000.

Rate Table Interpretation – Time Period

Each row in the report represents one year

National Healthcare Safety Network Rate Table for Incidence of Hospital-onset Antimicrobial Resistance by Phenotype (per 10,000 patient days) As of: March 8, 2023 at 5:59 PM Date Range: ANTIBIOGRAMRATES_HO_PHEN summaryYr 2021 to 2022 if (((phenotype_AR = "carbNS_Acine_AR")))

Facility Org ID=10009 Phenotype Description=Carbapenem-non-susceptible Acinetobacter spp.

Phenotype_AR	Summary Yr	Patient Days	Blood Count	Blood Incidence Rate	CSF Count	CSF Incidence Rate	LRS Count	LRS Incidence Rate	Urine Count	Urine Incidence Rate	All Specimen Type Count	All Specimen Type Incidence Rate
carbNS_Acine_AR	2021	4785	0	0	0	0	1	2.09	3	6.27	4	8.36
carbNS_Acine_AR	2022	5150	5	9.71	4	7.77	18	34.95	4	7.77	31	60.19

1. This phenotype includes any Acinetobacter spp. that has tested either Intermediate (I) or Resistant (R) to imipenem, meropenem, or doripenem.

2. Incidence: number of hospital-onset AR Events / patient days * 10,000.

Rate Table Interpretation – Patient Days

 Patients contributed 4785 patient days for all facility inpatient locations in 2021 and 5150 patient days for all facility inpatient locations in 2022

National Healthcare Safety Network Rate Table for Incidence of Hospital-onset Antimicrobial Resistance by Phenotype (per 10,000 patient days) As of: March 8, 2023 at 5:59 PM Date Range: ANTIBIOGRAMRATES_HO_PHEN summaryYr 2021 to 2022

if (((phenotype_AR = "carbNS_Acine_AR")))

Facility Org ID=10009 Phenotype Description=Carbapenem-non-susceptible Acinetobacter spp.

Phenotype_AR	Summary Yr	Patient Days	Blood Count	Blood Incidence Rate	CSF Count	CSF Incidence Rate	LRS Count	LRS Incidence Rate	Urine Count	Urine Incidence Rate	All Specimen Type Count	All Specimen Type Incidence Rate
carbNS_Acine_AR	2021	4785	0	0	0	0	1	2.09	3	6.27	4	8.36
carbNS_Acine_AR	2022	5150	5	9.71	4	7.77	18	34.95	4	7.77	31	60.19

1. This phenotype includes any Acinetobacter spp. that has tested either Intermediate (I) or Resistant (R) to imipenem, meropenem, or doripenem.

2. Incidence: number of hospital-onset AR Events / patient days * 10,000.

Rate Table Components – Counts

- Blood Count: Number of hospital-onset AR events isolated from blood
- CSF Count: Number of hospital-onset AR events isolated from CSF
- LRS Count: Number of hospital-onset AR events isolated from lower respiratory specimen
- Urine Count: Number of hospital-onset AR events isolated from urine
- All Specimen Type Count: Total number of hospital-onset AR events

Rate Table Interpretation – Counts

- There were 4 carbapenem-non-susceptible Acinetobacter spp. isolated in 2021: 0 from blood, 0 from CSF, 1 from lower respiratory, and 3 from urine
- There were **31** carbapenem-non-susceptible *Acinetobacter* spp. isolated in 2022: 5 from blood, 4 from CSF, 18 from lower respiratory, and 4 from urine

National Healthcare Safety Network Rate Table for Incidence of Hospital-onset Antimicrobial Resistance by Phenotype (per 10,000 patient days) As of: March 8, 2023 at 5:59 PM Date Range: ANTIBIOGRAMRATES_HO_PHEN summaryYr 2021 to 2022 if (((phenotype_AR = "carbNS_Acine_AR")))

Facility Org ID=10009 Phenotype Description=Carbapenem-non-susceptible Acinetobacter spp.

Phenotype_AR	Summary Yr	Patient Days	Blood Count	Blood Incidence Rate	CSF Count	CSF Incidence Rate	LRS Count	LRS Incidence Rate	Urine Count	Urine Incidence Rate	All Specimen Type Count	All Specimen Type Incidence Rate
carbNS_Acine_AR	2021	4785	0	0	0	0	1	2.09	3	6.27	4	8.36
carbNS_Acine_AR	2022	5150	5	9.71	4	7.77	18	34.95	4	7.77	31	60.19

1. This phenotype includes any Acinetobacter spp. that has tested either Intermediate (I) or Resistant (R) to imipenem, meropenem, or doripenem.

2. Incidence: number of hospital-onset AR Events / patient days * 10,000.

Incidence Rate per 10,000 Patient Days

Hospital—onset AR Events # Patient Days ×10,000

Rate Table Components – Incidence Rates per 10,000 Patient Days

- Blood Incidence Rate: Hospital-onset AR events that meet the AR phenotype definition isolated from blood per 10,000 patient days
- **CSF Incidence Rate**: Hospital-onset AR events that meet the AR phenotype definition isolated from CSF per 10,000 patient days
- LRS Incidence Rate: Hospital-onset AR events that meet the AR phenotype definition isolated from lower respiratory specimen per 10,000 patient days
- Urine Incidence Rate: Hospital-onset AR events that meet the AR phenotype definition isolated from urine per 10,000 patient days
- All Specimen Type Incidence Rate: Total hospital-onset AR events that meet the AR phenotype definition per 10,000 patient days

Rate Table Interpretation – Incidence Rates per 10,000 Patient Days

- Incidence rates of hospital-onset carbapenem-non-susceptible *Acinetobacter* spp. in 2021:
 - Blood = **0**
 - CSF = **0**
 - Lower respiratory = 2.09 events per 10,000 patient days
 - Urine = 6.27 events per 10,000 patient days
- The overall incidence rate of hospital-onset carbapenem-non-susceptible Acinetobacter spp. in 2021 was 8.36 events per 10,000 patient days

National Healthcare Safety Network Rate Table for Incidence of Hospital-onset Antimicrobial Resistance by Phenotype (per 10,000 patient days) As of: March 8, 2023 at 5:59 PM Date Range: ANTIBIOGRAMRATES_HO_PHEN summaryYr 2021 to 2022 if (((phenotype_AR = "carbNS_Acine_AR")))

Facility Org ID=10009 Phenotype Description=Carbapenem-non-susceptible Acinetobacter spp.

Phenotype_AR	Summary Yr	Patient Days	Blood Count	Blood Incidence Rate	CSF Count	CSF Incidence Rate	LRS Count	LRS Incidence Rate	Urine Count	Urine Incidence Rate	All Specimen Type Count	All Specimen Type Incidence Rate
carbNS_Acine_AR	2021	4785	0	0	0	0	1	2.09	3	6.27	4	8.36
carbNS_Acine_AR	2022	5150	5	9.71	4	7.77	18	34.95	4	7.77	31	60.19

1. This phenotype includes any Acinetobacter spp. that has tested either Intermediate (I) or Resistant (R) to imipenem, meropenem, or doripenem.

2. Incidence: number of hospital-onset AR Events / patient days * 10,000.

Rate Table Interpretation – Incidence Rates per 10,000 Patient Days

- Incidence rates of hospital-onset carbapenem-non-susceptible *Acinetobacter* spp. in 2022:
 - Blood = 9.71 events per 10,000 patient days
 - CSF = 7.77 events per 10,000 patient days
 - Lower respiratory = 34.95 events per 10,000 patient days
 - Urine = 7.77 events per 10,000 patient days
- The overall incidence rate of hospital-onset carbapenem-non-susceptible Acinetobacter spp. in 2022 was
 60.19 events per 10,000 patient days

National Healthcare Safety Network Rate Table for Incidence of Hospital-onset Antimicrobial Resistance by Phenotype (per 10,000 patient days) As of: March 8, 2023 at 5:59 PM Date Range: ANTIBIOGRAMRATES_HO_PHEN summaryYr 2021 to 2022 if (((phenotype_AR = "carbNS_Acine_AR")))

Facility Org ID=10009 Phenotype Description=Carbapenem-non-susceptible Acinetobacter spp.

Phenotype_AR	Summary Yr	Patient Days	Blood Count	Blood Incidence Rate	CSF Count	CSF Incidence Rate	LRS Count	LRS Incidence Rate	Urine Count	Urine Incidence Rate	All Specimen Type Count	All Specimen Type Incidence Rate
carbNS_Acine_AR	2021	4785	0	0	0	0	1	2.09	3	6.27	4	8.36
carbNS_Acine_AR	2022	5150	5	9.71	4	7.77	18	34.95	4	7.77	31	60.19

1. This phenotype includes any Acinetobacter spp. that has tested either Intermediate (I) or Resistant (R) to imipenem, meropenem, or doripenem.

2. Incidence: number of hospital-onset AR Events / patient days * 10,000.

Example: Rate Table – Community-onset Positive Culture Prevalence by Organism Report (New Rate Table #5)

Note: The following example uses fictitious data for illustrative purposes only.

Modifying the Rate Table



Rate Table – Modifications

- We would like to look at the community-onset prevalence rate of Enterobacterales (*E. coli, Enterobacter, Klebsiella*) for the first and second halves of 2021.
- Time Period: 2021 2021
- Filters: pathogenGroup=Enterobacterales_all
- Display Options: GroupBy = Summary Half-Year

Rate Table – Output

National Healthcare Safety Network Rate Table for Prevalence of Community-onset Organism-specific Events (per 10,000 admissions) As of: March 8, 2023 at 6:19 PM Date Range: ANTIBIOGRAMRATES_CO_ORG summaryYr 2021 to 2021 if (((PathogenGroup = "Enterobacterales_all")))

Facility Org ID=10009 pathogenGroup=Enterobacterales_all

Pathogen	Summary Yr/Half	Admissions	Blood Count	Blood Prevalence Rate	CSF Count	CSF Prevalence Rate	LRS Count	LRS Prevalence Rate	Urine Count	Urine Prevalence Rate	All Specimen Type Count	All Specimen Type Prevalence Rate
Enterobacterales_all	2021H1	824	2	24.27	1	12.14	1	12.14	1	12.14	5	60.68
Enterobacterales_all	2021H2	842	4	47.51	0	0	0	0	1	11.88	5	59.38

Prevalence: number of community-onset AR Events (including events from inpatient and outpatient locations) / admissions * 10,000.
 Includes Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, and Enterobacter spp.
 Data contained in this report were last generated on March 8, 2023 at 9:15 AM to include all data .

Rate Table Interpretation – Pathogen Group

- Rate table for prevalence of community-onset Enterobacterales (*E. coli, Enterobacter, Klebsiella*) per 10,000 admissions
 - Includes Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, and Enterobacter spp.

National Hea Rate Table for As of: March 8, 2023 a Date Range: ANTIBIO if (((PathogenGroup = Facility Org II	althcare	Safety Net lence of Co co_ORG summary ales_all"))) pathogenGi	work ommunity YYr 2021 to 2021 roup=Ente	/-onset Organisr erobacterales_all	n-specifi	c Events (per 1	0,000 a	dmissions)					
Pathogen	Summary PathogenSummary Yr/HalfBlood AdmissionsBlood Prevalence RateCSF CountCSF Prevalence RateLRS CountLRS Prevalence RateUrine CountUrine Prevalence RateAll Specimen Type Prevalence Rate												
Enterobacterales_all	2021H1	824	2	24.27	1	12.14	1	12.14	1	12.14	5	60.68	
Enterobacterales_all	nterobacterales_all 2021H2 842 4 47.51 0 0 0 0 0 1 11.88 55.										59.38		

1. Prevalence: number of community-onset AR Events (including events from inpatient and outpatient locations) / admissions * 10,000.

2. Includes Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, and Enterobacter spp.

Rate Table Interpretation – Time Period

Each row in the report represents one half-year of 2021

National Healthcare Safety Network Rate Table for Prevalence of Community-onset Organism-specific Events (per 10,000 admissions) As of: March 8, 2023 at 6:19 PM Date Range: ANTIBIOGRAMRATES_CO_ORG summaryYr 2021 to 2021 if (((PathogenGroup = "Enterobacterales all")))

Facility Org ID=10009 pathogenGroup=Enterobacterales_all

Pathogen	Summary Yr/Half	Admissions	Blood Count	Blood Prevalence Rate	CSF Count	CSF Prevalence Rate	LRS Count	LRS Prevalence Rate	Urine Count	Urine Prevalence Rate	All Specimen Type Count	All Specimen Type Prevalence Rate
Enterobacterales_all	2021H1	824	2	24.27	1	12.14	1	12.14	1	12.14	5	60.68
Enterobacterales_all	2021H2	842	4	47.51	0	0	0	0	1	11.88	5	59.38

Prevalence: number of community-onset AR Events (including events from inpatient and outpatient locations) / admissions * 10,000.
 Includes Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, and Enterobacter spp.
 Data contained in this report were last generated on March 8, 2023 at 9:15 AM to include all data .

Rate Table Interpretation – Admissions

There were 824 admissions to the facility's inpatient locations in 2021H1 and 842 admissions to the facility's inpatient locations in 2021H2

National Healthcare Safety Network Rate Table for Prevalence of Community-onset Organism-specific Events (per 10,000 admissions) As of: March 8, 2023 at 6:19 PM Date Range: ANTIBIOGRAMRATES_CO_ORG summaryYr 2021 to 2021 if (((PathogenGroup = "Enterobacterales_all")))

Facility Org ID=10009 pathogenGroup=Enterobacterales_all

Summ Pathogen Yr/Ha	ry f Admissions	Blood Count	Blood Prevalence Rate	CSF Count	CSF Prevalence Rate	LRS Count	LRS Prevalence Rate	Urine Count	Urine Prevalence Rate	All Specimen Type Count	All Specimen Type Prevalence Rate
Enterobacterales_all 2021H1	824	2	24.27	1	12.14	1	12.14	1	12.14	5	60.68
Enterobacterales_all 2021H2	842	4	47.51	0	0	0	0	1	11.88	5	59.38

1. Prevalence: number of community-onset AR Events (including events from inpatient and outpatient locations) / admissions * 10,000.

2. Includes Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, and Enterobacter spp.

Rate Table Components – Counts

- Blood Count: Number of community-onset AR events isolated from blood
- CSF Count: Number of community-onset AR events isolated from CSF
- LRS Count: Number of community-onset AR events isolated from lower respiratory specimen
- Urine Count: Number of community-onset AR events isolated from urine
- All Specimen Type Count: Total number of community-onset AR events

Rate Table Interpretation – Counts

- There were 5 Enterobacterales (*E. coli, Enterobacter, Klebsiella*) isolated in 2021H1: 2 from blood, 1 from CSF, 1 from lower respiratory, and 1 from urine
- There were 5 Enterobacterales (*E. coli, Enterobacter, Klebsiella*) isolated in 2021H2: 4 from blood, 0 from CSF, 0 from lower respiratory, and 1 from urine

National Hea	Ithcare \$	Safety Net	work									
Rate Table for As of: March 8, 2023 at Date Range: ANTIBIOC if (((PathogenGroup =	or Preval t 6:19 PM GRAMRATES_C "Enterobacter	lence of C CO_ORG summar ales_all")))	ommunity yYr 2021 to 2021	/-onset Organisr	n-specif	fic Events (per 1	10,000 ad	dmissions)				
Facility Org I	acility Org ID=10009 pathogenGroup=Enterobacterales_all											
PathogenSummary Yr/HalfBloodBloodPrevalence RateCSF CountCSF Prevalence RateLRS CountLRS Prevalence RateUrine CountUrine Prevalence RateAll Specimen Type Prevalence Rate												
Enterobacterales all	2021H1	824	2	24.27	1	12 14	1	12 14	1	12 14	5	60.68

5

59.38

11.88

1. Prevalence: number of community-onset AR Events (including events from inpatient and outpatient locations) / admissions * 10,000.

47.51

0

2. Includes Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, and Enterobacter spp.

Data contained in this report were last generated on March 8, 2023 at 9:15 AM to include all data .

Enterobacterales all 2021H2

Prevalence Rate per 10,000 Admissions

Community-onset AR Events from inpatient and outpatient locations # Admissions

Rate Table Components – Prevalence Rates per 10,000 Admissions

- Blood Prevalence Rate: Community-onset AR events isolated from blood per 10,000 admissions
- CSF Prevalence Rate: Community-onset AR events isolated from CSF per 10,000 admissions
- LRS Prevalence Rate: Community-onset AR events isolated from lower respiratory specimen per 10,000 admissions
- Urine Prevalence Rate: Community-onset AR events isolated from urine per 10,000 admissions
- All Specimen Type Prevalence Rate: Total community-onset AR events per 10,000 admissions

Rate Table Interpretation – Prevalence Rates per 10,000 Admissions

- Prevalence rates of community-onset Enterobacterales (*E. coli, Enterobacter, Klebsiella*) in 2021H1:
 - Blood = 24.27 events per 10,000 admissions
 - CSF = **12.14** events per 10,000 admissions
 - Lower respiratory = 12.14 events per 10,000 admissions
 - Urine = 12.14 events per 10,000 admissions
- The overall prevalence rate of community-onset Enterobacterales (*E. coli, Enterobacter, Klebsiella*) in 2021H1 was 60.68 events per 10,000 admissions

National Healthcare Safety Network Rate Table for Prevalence of Community-onset Organism-specific Events (per 10,000 admissions) As of: March 8, 2023 at 6:19 PM Date Range: ANTIBIOGRAMRATES_CO_ORG summaryYr 2021 to 2021 if (((PathogenGroup = "Enterobacterales all")))

Facility Org ID=10009 pathogenGroup=Enterobacterales_all

Pathogen	Summary Yr/Half	Admissions	Blood Count	Blood Prevalence Rate	CSF Count	CSF Prevalence Rate	LRS Count	LRS Prevalence Rate	Urine Count	Urine Prevalence Rate	All Specimen Type Count	All Specimen Type Prevalence Rate
Enterobacterales_all	2021H1	824	2	24.27	1	12.14	1	12.14	1	12.14	5	60.68
Enterobacterales_all	2021H2	842	4	47.51	0	0	0	0	1	11.88	5	59.38

1. Prevalence: number of community-onset AR Events (including events from inpatient and outpatient locations) / admissions * 10,000.

2. Includes Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, and Enterobacter spp.

Rate Table Interpretation – Prevalence Rates per 10,000 Admissions

- Prevalence rates of community-onset Enterobacterales (*E. coli, Enterobacter, Klebsiella*) in 2021H2:
 - Blood = 47.51 events per 10,000 admissions
 - CSF = **0**
 - Lower respiratory = 0
 - Urine = 11.88 events per 10,000 admissions
- The overall prevalence rate of community-onset Enterobacterales (*E. coli, Enterobacter, Klebsiella*) in 2021H2 was 59.38 events per 10,000 admissions

National Healthcare Safety Network Rate Table for Prevalence of Community-onset Organism-specific Events (per 10,000 admissions) As of: March 8, 2023 at 6:19 PM Date Range: ANTIBIOGRAMRATES_CO_ORG summaryYr 2021 to 2021

if (((PathogenGroup = "Enterobacterales_all")))

Facility Org ID=10009 pathogenGroup=Enterobacterales_all

Pathogen	Summary Yr/Half	Admissions	Blood Count	Blood Prevalence Rate	CSF Count	CSF Prevalence Rate	LRS Count	LRS Prevalence Rate	Urine Count	Urine Prevalence Rate	All Specimen Type Count	All Specimen Type Prevalence Rate
Enterobacterales_all	2021H1	824	2	24.27	1	12.14	1	12.14	1	12.14	5	60.68
Enterobacterales_all	2021H2	842	4	47.51	0	0	0	0	1	11.88	5	59.38

1. Prevalence: number of community-onset AR Events (including events from inpatient and outpatient locations) / admissions * 10,000.

2. Includes Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, and Enterobacter spp.

What happens when denominator data are not reported for a time period?

Note: The following example uses fictitious data for illustrative purposes only.

Missing Denominator Data for a Month

- If denominator data (i.e., patient days, admissions, encounters) are not reported for a month, but AR events were reported for that month, then the AR events for that month will be excluded from the counts and rates for the rollup (e.g., quarter, half-year, year, cumulative).
- For example, encounters were reported for the ED for January and February 2022, and CRE AR events were reported for the ED for January, February, and March 2022.
 - The CRE AR events from March 2022 will not be included in the CRE outpatient prevalence rates for 2022Q1.

Missing Denominator Data for a Full Time Period

If denominator data (i.e., patient days, admissions, encounters) are not reported for all three months in a quarter or all six months in a half-year or all 12 months of a year, or at all, but AR events were reported for that time period, then the AR events will be included in the counts, but the denominator and rates will be suppressed.

National Rate Tab As of: March 8, Date Range: Al OrgID=100	National Healthcare Safety Network Rate Table for Prevalence of Outpatient Organism-specific Events (per 10,000 encounters) As of: March 8, 2023 at 6:35 PM Date Range: All ANTIBIOGRAMRATES_OP_ORG orgID=10009 pathogenGroup=Enterococcus											
Pathogen	summaryYQ	Encounters	Blood Count	Blood Prevalence Rate	CSF Count	CSF Prevalence Rate	LRS Count	LRS Prevalence Rate	Urine Count	Urine Prevalence Rate	All Specimen Type Count	All Specimen Type Prevalence Rate
Enterococcus 2021Q1 . 1 . 0 . 0 . 0 . 1 . 1												
Enterococcus 2022Q1 0 0 0 0 3 0 8												

1. Prevalence: number of community-onset AR Events (events from outpatient locations only) / encounters * 10,000.

2. Includes Enterococcus spp. including Enterococcus faecalis, Enterococcus faecium, and any species that belong to the genus Enterococcus.



AUR Module Webpage

- Direct link: <u>https://www.cdc.gov/nhsn/psc/aur/index.html</u>
- One-stop shop for:
 - Protocol
 - Validation material
 - Link to training resources
 - Link to Analysis Quick Reference Guides
 - Link to FAQs
 - Link to CDA Toolkits

AR Option Resources

- NHSN AUR Protocol:
 - <u>http://www.cdc.gov/nhsn/PDFs/pscManual/11pscAURcurrent.pdf</u>
- NHSN Analysis Quick Reference Guides:
 - <u>http://www.cdc.gov/nhsn/PS-Analysis-resources/reference-guides.html</u>
- NHSN CDA Submission Support Portal:
 - <u>https://www.cdc.gov/nhsn/cdaportal/index.html</u>
- NHSN Helpdesk (protocol, submission, and analysis questions):
 - <u>NHSN@cdc.gov</u>
- NHSN CDA Helpdesk (technical CDA related questions):
 - <u>NHSNCDA@cdc.gov</u>

Thank you!

For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

